Clinical trial
Adjunctive Ziprasidone in the Treatment of Bipolar I Depression
NCT00483548 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry · Completed
Key facts
| NCT number | NCT00483548 |
|---|---|
| Title | Adjunctive Ziprasidone in the Treatment of Bipolar I Depression |
| Official title | A Six-Week, Double-Blind, Multicenter, Placebo Controlled Study Evaluating The Efficacy And Safety Of Flexible Doses Of Oral Ziprasidone As Add-On, Adjunctive Therapy With Lithium, Valproate Or Lamotrigine In Bipolar I Depression |
| Lead sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Bipolar Disorder, Depression, Bipolar |
| Intervention type | Drug |
| Interventions | Ziprasidone, Placebo |
| Enrollment | 298 |
| Start date | Oct 1, 2007 |
| Primary completion | Dec 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Jun 7, 2007 |
| Last update posted | Mar 10, 2021 |
| Countries | Australia, India, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: